Filspari
What Filspari is used for
Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1.0 g/day (or urine protein-to-creatinine ratio > 0.75 g/g, see section 5.1).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Filspari
- Active substance
- sparsentan
- Disease area
- Glomerulonephritis, IGA
- Medicine group
- Agents acting on the renin-angiotensin system
- ATC code
- C09XX01
- Marketing authorisation holder
- Vifor France
- Authorised in the EU since
- 2024
Official information
In the USA
Same active substance: Filspari
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Filspari used for?
Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1.0 g/day (or urine protein-to-creatinine ratio > 0.75 g/g, see section 5.1).
What is the active substance in Filspari?
Filspari contains sparsentan.
Who makes Filspari?
The EU marketing authorisation holder is Vifor France.
Is Filspari an orphan medicine?
Yes. Filspari is designated an orphan medicine in the EU, for a rare disease (Glomerulonephritis, IGA).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU